{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03395028",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CR00005169"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "IND 119679-0007",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "Food and Drug Administration"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Holterman, Ai-Xuan, M.D.",
        "OrgClass": "INDIV"
      },
      "BriefTitle": "GCSF Adjunct Therapy for Biliary Atresia",
      "OfficialTitle": "Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia",
      "Acronym": "BA_GCSF"
    },
    "StatusModule": {
      "StatusVerifiedDate": "February 2020",
      "OverallStatus": "Completed",
      "StartDateStruct": {
        "StartDate": "January 15, 2018",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 31, 2020",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 31, 2020",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "December 22, 2017",
      "StudyFirstSubmitQCDate": "January 3, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "January 9, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "February 12, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "February 17, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Holterman, Ai-Xuan, M.D.",
        "LeadSponsorClass": "INDIV"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "T. Rose Clinical, Inc., United States",
            "CollaboratorClass": "UNKNOWN"
          },
          {
            "CollaboratorName": "Children's National Health System",
            "CollaboratorClass": "OTHER"
          },
          {
            "CollaboratorName": "Big Leap Research, Vietnam",
            "CollaboratorClass": "UNKNOWN"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The Investigators propose to test the hypothesis that GCSF therapy enhances the clinical outcome of Kasai operated Biliary Atresia (BA) patients. In this study, Investigators will conduct a dose determination for GCSF use in post Kasai subjects to support a future phase 2 efficacy study. The first 3 post Kasai BA subjects with liver biopsy-confirmed BA will be given 5 ug/kg/d of GCSF in 3 daily subcutaneous doses starting on post Kasai day 3. A second group of 3 subjects will be assigned to the 10 ug/Kg/d dose after the 5ug/kg/d dose has been proven to be safe. The levels of circulating hematopoietic stem cells and a 1-month safety profile will be analyzed.",
      "DetailedDescription": "In BA, neonatal fibrous obliteration of the biliary tract obstructs biliary drainage and promotes biliary fibrosis. BA is the leading cause of pediatric chronic end-stage liver disease and pediatric liver transplantation. Relief of cholestasis by the Kasai portoenterostomy is only partly successful with continued progression of fibrosis to hepatic insufficiency and, for long term survival, with eventual need for liver transplantation in the majority of the patients. In animal models of liver injury, GCSF enhances hematopoietic stem cell HSC mobilization and engraftment in the liver with associated improved liver repair response and attenuated hepatic necrosis and fibrosis. Randomized controlled trials of GCSF intervention for chronic liver failure in adult patients with acute hepatic decompensation showed improved short-term survival and hepatic indices such the model for end-stage liver disease (MELD) scores.\n\nThe Investigators propose that post Kasai GCSF therapy attenuates biliary fibrosis and progression to cirrhosis. The objectives are meant to demonstrate that Kasai-GCSF sequential therapy improves biliary drainage, and delays the progression of hepatic insufficiency. Toward this goal, Investigators will first evaluate in post Kasai subjects the maximum tolerated dose of GCSF in mobilizing circulating CD34+ hematopoietic stem cells, with the limiting dose based on GCSF-related severe adverse effects. A one-month safety of GCSF will be tested with the 2 standard doses of 5 ug/kg/d and 10 ug/kg/d."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Biliary Atresia"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Biliary Atresia",
          "Granulocyte Colony Stimulating Factor",
          "GCSF"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Early Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignInterventionModelDescription": "Dose determination for GCSF",
        "DesignPrimaryPurpose": "Supportive Care",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "6",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Granulocyte Colony-Stimulating Factor",
            "InterventionDescription": "G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGENÂ® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.",
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Filgrastim"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Dose determination GCSF",
            "PrimaryOutcomeDescription": "To determine the maximum tolerated dose of GCSF based on GCSF dose limiting toxicity and the extent of peripheral blood stem cell mobilization as measured by increases in CD34+cells with upper levels limited by white blood cells (WBCs) less than 50,000 per microliter (mcL) of blood.",
            "PrimaryOutcomeTimeFrame": "13 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nCompleted the preliminary work up for cholestasis with suspected or inconclusive diagnosis of BA\nGestational Age > 36wks\nWeight > 2 Kg\nAge >-2 weeks-<180 days at diagnosis\nSerum Direct Bilirubin > 2 mg/dL GGT > 100 U/L\nKasai operated patients for Type 3 or 4 anatomy of BA\nCholangiogram/porta hepatis findings diagnostic of BA\nLiver biopsy supporting BA diagnosis\n\nExclusion Criteria:\n\nHaving access to liver transplantation for immediate Kasai failure\nPrior Kasai patients\nMajor cardiac, renal, CNS malformations with poor prognosis\nIntracranial hemorrhage\nHistory of recent TPN use within the last 2 weeks of surgery\nGI tract obstruction\nLaparoscopic Kasai repair",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MaximumAge": "180 Days",
      "StdAgeList": {
        "StdAge": [
          "Child"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Evan P Nadler, MD",
            "OverallOfficialAffiliation": "Children's National Research Institute",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Children's National Medical Center",
            "LocationCity": "Washington",
            "LocationState": "District of Columbia",
            "LocationZip": "20010",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "National Childrens Hospital",
            "LocationCity": "Hanoi",
            "LocationCountry": "Vietnam"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "22800970",
            "ReferenceType": "background",
            "ReferenceCitation": "Davenport M. Biliary atresia: clinical aspects. Semin Pediatr Surg. 2012 Aug;21(3):175-84. doi: 10.1053/j.sempedsurg.2012.05.010. Review."
          },
          {
            "ReferencePMID": "18400509",
            "ReferenceType": "background",
            "ReferenceCitation": "Panopoulos AD, Watowich SS. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine. 2008 Jun;42(3):277-88. doi: 10.1016/j.cyto.2008.03.002. Epub 2008 Apr 8. Review."
          },
          {
            "ReferencePMID": "15661404",
            "ReferenceType": "background",
            "ReferenceCitation": "Yannaki E, Athanasiou E, Xagorari A, Constantinou V, Batsis I, Kaloyannidis P, Proya E, Anagnostopoulos A, Fassas A. G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs. Exp Hematol. 2005 Jan;33(1):108-19."
          },
          {
            "ReferencePMID": "22395569",
            "ReferenceType": "background",
            "ReferenceCitation": "Takami T, Terai S, Sakaida I. Stem cell therapy in chronic liver disease. Curr Opin Gastroenterol. 2012 May;28(3):203-8. doi: 10.1097/MOG.0b013e3283521d6a. Review."
          },
          {
            "ReferencePMID": "27930386",
            "ReferenceType": "background",
            "ReferenceCitation": "Prajapati R, Arora A, Sharma P, Bansal N, Singla V, Kumar A. Granulocyte colony-stimulating factor improves survival of patients with decompensated cirrhosis: a randomized-controlled trial. Eur J Gastroenterol Hepatol. 2017 Apr;29(4):448-455. doi: 10.1097/MEG.0000000000000801."
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001656",
            "ConditionMeshTerm": "Biliary Atresia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000001649",
            "ConditionAncestorTerm": "Bile Duct Diseases"
          },
          {
            "ConditionAncestorId": "D000001660",
            "ConditionAncestorTerm": "Biliary Tract Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          },
          {
            "ConditionAncestorId": "D000004065",
            "ConditionAncestorTerm": "Digestive System Abnormalities"
          },
          {
            "ConditionAncestorId": "D000000013",
            "ConditionAncestorTerm": "Congenital Abnormalities"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M4094",
            "ConditionBrowseLeafName": "Biliary Atresia",
            "ConditionBrowseLeafAsFound": "Biliary Atresia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4087",
            "ConditionBrowseLeafName": "Bile Duct Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4098",
            "ConditionBrowseLeafName": "Biliary Tract Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12",
            "ConditionBrowseLeafName": "Congenital Abnormalities",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6406",
            "ConditionBrowseLeafName": "Digestive System Abnormalities",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T757",
            "ConditionBrowseLeafName": "Biliary Atresia",
            "ConditionBrowseLeafAsFound": "Biliary Atresia",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC16",
            "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionMeshList": {
        "InterventionMesh": [
          {
            "InterventionMeshId": "D000078224",
            "InterventionMeshTerm": "Lenograstim"
          },
          {
            "InterventionMeshId": "C000081222",
            "InterventionMeshTerm": "Sargramostim"
          }
        ]
      },
      "InterventionAncestorList": {
        "InterventionAncestor": [
          {
            "InterventionAncestorId": "D000000276",
            "InterventionAncestorTerm": "Adjuvants, Immunologic"
          },
          {
            "InterventionAncestorId": "D000007155",
            "InterventionAncestorTerm": "Immunologic Factors"
          },
          {
            "InterventionAncestorId": "D000045505",
            "InterventionAncestorTerm": "Physiological Effects of Drugs"
          }
        ]
      },
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M244297",
            "InterventionBrowseLeafName": "Sargramostim",
            "InterventionBrowseLeafAsFound": "Electrodes",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M1945",
            "InterventionBrowseLeafName": "Lenograstim",
            "InterventionBrowseLeafAsFound": "Tip",
            "InterventionBrowseLeafRelevance": "high"
          },
          {
            "InterventionBrowseLeafId": "M273811",
            "InterventionBrowseLeafName": "polysaccharide-K",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M257523",
            "InterventionBrowseLeafName": "Molgramostim",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M2780",
            "InterventionBrowseLeafName": "Adjuvants, Immunologic",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M9353",
            "InterventionBrowseLeafName": "Immunologic Factors",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          },
          {
            "InterventionBrowseBranchAbbrev": "Infe",
            "InterventionBrowseBranchName": "Anti-Infective Agents"
          },
          {
            "InterventionBrowseBranchAbbrev": "ANeo",
            "InterventionBrowseBranchName": "Antineoplastic Agents"
          }
        ]
      }
    }
  }
}